Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transthyretin-mediated Amyloidosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05071300
What this trial is testing

Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Who this might be right for
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Ionis Pharmaceuticals, Inc. 151
Large-scale testing (Phase 3)Active Not RecruitingNCT04153149
What this trial is testing

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 655
Testing effectiveness (Phase 2)Active Not RecruitingNCT07608354
What this trial is testing

Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

Who this might be right for
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca 326
Post-approval studies (Phase 4)Ended earlyNCT04306510
What this trial is testing

Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN

Who this might be right for
Hereditary Transthyretin Amyloidosis With Polyneuropthy
Akcea Therapeutics 8
Not applicableNo Longer AvailableNCT05505838
What this trial is testing

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin-mediated Amyloidosis With CardiomyopathyATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Large-scale testing (Phase 3)Enrolling By InvitationNCT05667493
What this trial is testing

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. 1,400
Large-scale testing (Phase 3)WithdrawnNCT04882735
What this trial is testing

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Eidos Therapeutics, a BridgeBio company
Early research (Phase 1)Study completedNCT02797847
What this trial is testing

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Who this might be right for
Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
Alnylam Pharmaceuticals 80
Large-scale testing (Phase 3)Looking for participantsNCT06128629
What this trial is testing

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics 1,200
Not applicableLooking for participantsNCT06465810
What this trial is testing

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Who this might be right for
Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca 1,850
Testing effectiveness (Phase 2)Study completedNCT01617967
What this trial is testing

Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 29
Large-scale testing (Phase 3)WithdrawnNCT04418024
What this trial is testing

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Eidos Therapeutics, a BridgeBio company
Testing effectiveness (Phase 2)Study completedNCT01961921
What this trial is testing

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 27
Large-scale testing (Phase 3)Looking for participantsNCT07223203
What this trial is testing

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Who this might be right for
Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN
Alnylam Pharmaceuticals 125
Not applicableLooking for participantsNCT07358078
What this trial is testing

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Who this might be right for
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals 2,000
Early research (Phase 1)Study completedNCT06527755
What this trial is testing

Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers

Who this might be right for
Transthyretin-mediated Amyloidosis
AstraZeneca 12
Testing effectiveness (Phase 2)Study completedNCT02292186
What this trial is testing

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 25
Large-scale testing (Phase 3)Study completedNCT02510261
What this trial is testing

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
Amyloidosis
Alnylam Pharmaceuticals 211
Not applicableStudy completedNCT04201418
What this trial is testing

Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

Who this might be right for
Hereditary Transthyretin-mediated (ATTRv) AmyloidosisPolyneuropathy
Alnylam Pharmaceuticals 67
Testing effectiveness (Phase 2)Study completedNCT01981837
What this trial is testing

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 26
Next Page